ALNY
Alnylam Pharmaceuticals, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers): holder breadth 0.0% · share flow -30.0% · net new positions 0.0% · formula
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2026
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 5 | 0 | 220.72K | $53.70M | n/a | n/a |
| Q2 2026 | 162 | +3 | 107.60M | $32.37B | +7 | −3 |
| Q1 2026 | 161 | -2 | 108.78M | $35.89B | +4 | −7 |
| Q4 2025 | 162 | -2 | 118.83M | $47.26B | +1 | −2 |
| Q3 2025 | 24 | +1 | 85.59M | $39.02B | +2 | −2 |
| Q2 2025 | 21 | -1 | 76.99M | $25.10B | n/a | −1 |
| Q1 2025 | 19 | +2 | 40.24M | $10.86B | +3 | −1 |
| Q4 2024 | 17 | 0 | 41.95M | $9.87B | n/a | n/a |
| Q3 2024 | 16 | +1 | 39.28M | $10.80B | +2 | −1 |
| Q2 2024 | 15 | n/a | 40.30M | $9.79B | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Assenagon Asset Management S.A. | 168.32K | -46.0% | $41.53M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 2 | Assetmark, Inc | 18.77K | +31.0% | $4.63M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 3 | Robeco Institutional Asset… | 14.34K | -92.4% | $3.54M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 4 | Wealth Enhancement Advisory… | 16.99K | +126.7% | $3.47M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 5 | TD Waterhouse Canada Inc. | 2.30K | +26.2% | $532,493 | 0.0% | ▲ Add | 4 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 781 holders, 122.25M shares, $37.95B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 1.76K sh · $398,855
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology